Skip To Main Content
Kim Barbara Luley on Muck Rack

Kim Barbara Luley

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kim Barbara

Contact Kim Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

|
By Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Dechow, Thomas Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel H. Pink, Udo Lindig, Gunnar Folprecht, Gunter Schuch, Michael Bitzer, Volker Heinemann, Stefan Angermeier, Claus Bolling, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran
| Nature Verified
Correction to: Nature Communications https://doi.org/10.1038/s41467-026-69622-7, published online 27 February 2026 In the version of this article initially published, funding information did not acknowledge the sponsor of the trial is the Frankfurt Institute of Clinical Cancer Research IKF GmbH and that financial support and drug supply for the conduct of the trial was granted by Bristol-Myers Squibb GmbH & Co. KGaA, while the title was incomplete and did not reference the Institut für...
Open in Who Shared Issue with article?

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial | Nature Communications

|
By Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Dechow, Thomas Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel H. Pink, Gunnar Folprecht, Michael Bitzer, Volker Heinemann, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran, Udo Lindig, Gunter Schuch, Stefan Angermeier, Claus Bolling
| Nature Verified
Abstract This multi-cohort study evaluates whether dual immune checkpoint inhibition with nivolumab and ipilimumab in parallel or sequentially, or triplet chemotherapy with nivolumab can enhance efficacy as first-line therapy for advanced or metastatic gastroesophageal adenocarcinoma. Patients are randomized 1:1 to Arm A (mFOLFOX + nivolumab 240 mg every two weeks + ipilimumab 1 mg/kg every six weeks in parallel or Arm B (mFOLFOX).
Open in Who Shared Issue with article?
|
By Matthias Egger, Salah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Nicole Prasnikar
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?
See all 3 articles